Rigel Entered into an Exclusive WW License Agreement with Forma to Develop and Commercialize Olutasidenib for Acute Myeloid Leukemia
Shots:
- Forma to receive $2.0M up front, $17.5M upon regulatory, approval & first commercial sale milestones, ~$215.5M in development & commercial milestones along with royalties
- Rigel will lead the launch & commercialization of olutasidenib in the US & is planning for outside the US with potential partners. The collaboration will advance Rigel's hematology-oncology portfolio & will use commercial capabilities for a new therapy
- In an interim analysis of the P-II registrational study, olutasidenib showed 33% CR+CRh in mIDH1+ r/r AML patients., 18mos. survival (87%) & the median duration of CR+CRh (not reached) and showed durable response & a favorable tolerability profile. The US FDA has accepted olutasidenib's NDA with an anticipated PDUFA date on Feb 15, 2023
Ref: Rigel | Image: Rigel Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
